GEN Exclusives

More »

GEN News Highlights

More »
Jul 31, 2013

Merck, Bionomics Make Potentially $172M Pact to Search for Chronic Pain Treatments

  • Bionomics, a drug discovery and development company based in Australia, is teaming up with Merck to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain. The initial period of the research program will be two years.

    Per the agreement, Merck will have the option to exclusively license a compound from Bionomics for development and commercialization; in exchange, Bionomics may receive development and regulatory milestone payments and option exercise fees of up to $172 million. Bionomics may also be eligible for undisclosed royalties on net sales of products from the collaboration.

    Bionomics will be using its ionX® drug discovery platform and MultiCore® chemistry to identify potential drug candidates as part of the deal. The firm describes ionX as a set of technologies for the identification of drugs targeting ion channels for CNS diseases, and MultiCore as a diversity-orientated chemistry platform for the discovery of small molecule drugs.

    "This research collaboration is a strong validation of our drug discovery platforms," said Sue O'Connor, Ph.D., vp of neuroscience research at Bionomics, in a statement.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?